SG11202009439YA - Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same - Google Patents

Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same

Info

Publication number
SG11202009439YA
SG11202009439YA SG11202009439YA SG11202009439YA SG11202009439YA SG 11202009439Y A SG11202009439Y A SG 11202009439YA SG 11202009439Y A SG11202009439Y A SG 11202009439YA SG 11202009439Y A SG11202009439Y A SG 11202009439YA SG 11202009439Y A SG11202009439Y A SG 11202009439YA
Authority
SG
Singapore
Prior art keywords
grow
live
same
vaccine composition
fever virus
Prior art date
Application number
SG11202009439YA
Inventor
Manuel Vangelisti
Nathalie Mantel
Yves Girerd-Chambaz
Fabienne Piras
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of SG11202009439YA publication Critical patent/SG11202009439YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • C12N7/08Inactivation or attenuation by serial passage of virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161Methods of inactivation or attenuation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161Methods of inactivation or attenuation
    • C12N2770/24164Methods of inactivation or attenuation by serial passage
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202009439YA 2018-04-06 2019-04-02 Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same SG11202009439YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18305405.5A EP3549603A1 (en) 2018-04-06 2018-04-06 Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same
PCT/EP2019/058268 WO2019192997A1 (en) 2018-04-06 2019-04-02 Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same

Publications (1)

Publication Number Publication Date
SG11202009439YA true SG11202009439YA (en) 2020-10-29

Family

ID=62046805

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202009439YA SG11202009439YA (en) 2018-04-06 2019-04-02 Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same

Country Status (15)

Country Link
US (2) US11471521B2 (en)
EP (2) EP3549603A1 (en)
JP (1) JP7370338B2 (en)
KR (1) KR20200140292A (en)
CN (1) CN111918669A (en)
AR (1) AR114471A1 (en)
AU (1) AU2019249329A1 (en)
BR (1) BR112020018879A2 (en)
CA (1) CA3095438A1 (en)
CO (1) CO2020011984A2 (en)
PE (1) PE20210317A1 (en)
SG (1) SG11202009439YA (en)
TW (1) TWI835787B (en)
WO (1) WO2019192997A1 (en)
ZA (1) ZA202006280B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3549603A1 (en) * 2018-04-06 2019-10-09 Sanofi Pasteur Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101959527B (en) 2008-03-05 2016-04-20 赛诺菲巴斯德有限公司 A kind of method that vaccine combination making to contain adjuvant is stable
CA3150411C (en) * 2009-07-31 2023-09-12 Pnuvax Inc. High yield yellow fever virus strain with increased propagation in cells
AR079970A1 (en) * 2010-07-23 2012-02-29 Xcellerex Inc HIGH PERFORMANCE VIRUSES OF THE YELLOW FEVER VIRUS WITH INCREASED PROPAGATION IN THE CELLS
SG11201500412TA (en) 2012-07-24 2015-02-27 Sanofi Pasteur Vaccine compositions
EP3549603A1 (en) * 2018-04-06 2019-10-09 Sanofi Pasteur Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same

Also Published As

Publication number Publication date
US20210154289A1 (en) 2021-05-27
TWI835787B (en) 2024-03-21
US11452772B2 (en) 2022-09-27
CO2020011984A2 (en) 2021-02-08
KR20200140292A (en) 2020-12-15
PE20210317A1 (en) 2021-02-16
RU2020136260A (en) 2022-05-06
US11471521B2 (en) 2022-10-18
JP2021520384A (en) 2021-08-19
WO2019192997A1 (en) 2019-10-10
CA3095438A1 (en) 2019-10-10
US20220047692A1 (en) 2022-02-17
EP3549603A1 (en) 2019-10-09
JP7370338B2 (en) 2023-10-27
CN111918669A (en) 2020-11-10
EP3773701A1 (en) 2021-02-17
AU2019249329A1 (en) 2020-12-03
ZA202006280B (en) 2022-06-29
BR112020018879A2 (en) 2021-01-26
TW202003028A (en) 2020-01-16
AR114471A1 (en) 2020-09-09

Similar Documents

Publication Publication Date Title
IL263373A (en) Genetically modified vaccinia virus, compositions containing same and uses thereof
HK1257074A1 (en) Oncolytic virus strain
MX2021006931A (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof.
HK1255192A1 (en) Modified oncolytic vaccinia viruses expressing a cytokine and a car-boxylesterase and methods of use thereof
EP3207145A4 (en) Copi coatomer gamma subunit nucleic acid molecules that confer resistance to coleopteran and hemipteran pests
EP3207051A4 (en) Copi coatomer alpha subunit nucleic acid molecules that confer resistance to coleopteran and hemipteran pests
EP3206495A4 (en) Copi coatomer delta subunit nucleic acid molecules that confer resistance to coleopteran and hemipteran pests
DK3197489T3 (en) PROCEDURES AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY TO HUMAN IMMUNE INFECTION VIRUS INFECTION
EP3012322A4 (en) Porcine pseudorabies virus gene deletion strain, vaccine composition, and preparation method therefor and application thereof
JO3765B1 (en) Therapeutic HPV18 vaccines
IL247469A0 (en) Il-15/il-15r alpha based conjugates purification methods, compositions containing products obtained thereby and uses thereof
SG11202003800YA (en) Zika vaccines and immunogenic compositions, and methods of using the same
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
EP3309251A4 (en) Human parainfluenza type 2 virus vector and vaccine
EP3305310A4 (en) Oncolytic virus formulation and preparation method thereof
EP3518947C0 (en) Optimized oncolytic viruses and uses thereof
SG11202004863QA (en) Zika vaccines and immunogenic compositions, and methods of using the same
SG11202106394PA (en) Adaptation of enterovirus to vero cells and vaccine formulations thereof
HK1253377A1 (en) Programmable vaccine system for oncolytic viruses and application of the same
HK1219500A1 (en) Genetically stable oncolytic rna virus, method of manufacturing and use thereof rna
HK1255379A1 (en) Hepatitis c virus immunogenic compositions and methods of use thereof
ZA201805159B (en) Mesenchymal stem cells as vaccine adjuvants and methods for using the same
WO2016100615A3 (en) Methods and composition for neutralization of influenza
MX2018014955A (en) Equine influenza virus live-attenuated vaccines.
ZA202006280B (en) Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same